Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | EEF2K | O00418 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5645167 | 0.84 | CNR2 (0.50) | CNR2GAACES2CES1LMNA | |
| SCHEMBL8750846 | 0.76 | MEN1 (0.47) | CNR2GAACES2CES1LMNA | |
| SCHEMBL6120380 | 0.76 | MEN1 (0.47) | CNR2GAACES2CES1LMNA | |
| SCHEMBL2482538 | 0.73 | GAA (0.45) | CNR2GAACES2CES1LMNA | |
| SCHEMBL23886691 | 0.72 | GAA (0.44) | CNR2GAACES2CES1LMNA | |
| Hydrochloric Acid SCHEMBL2485774 | 0.72 | GAA (0.44) | CNR2GAACES2CES1LMNA | |
| SCHEMBL23886688 | 0.72 | GAA (0.44) | CNR2GAACES2CES1LMNA | |
| SCHEMBL23886587 | 0.72 | CTSS (0.49) | CNR2GAA | |
| SCHEMBL30370355 | 0.72 | CTSS (0.49) | CNR2GAA | |
| SCHEMBL30370648 | 0.72 | CTSS (0.49) | CNR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226943-B2 | Benzothiepine ileal bile acid transport inhibitors | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | disclosed |
| EP-1427718-B1 | BENZOTHIEPINE ILEAL BILE ACID TRANSPORT INHIBOTORS | ASTRAZENECA AB (SE) | 2006-11-15 | — | — | EP | disclosed |
| US-20050043393-A1 | Benzothiepine ileal bile acid transport inhibitors | ASTRAZENECA AB | 2005-02-24 | — | — | US | disclosed |
| EP-1427718-A1 | BENZOTHIEPINE ILEAL BILE ACID TRANSPORT INHIBOTORS | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003022830-A1 | BENZOTHIEPINE ILEAL BILE ACID TRANSPORT INHIBITORS | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043393-A1 | Benzothiepine ileal bile acid transport inhibitors | SLC10A2, SLC10A1, ABCB11 | CNR2 2643/4885GAA 1122/4885CES2 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.